National Research Corporation (NRC) AI Stock Analysis

National Research Corporation operates as a provider of analytics and insights that drive improvements in patient and employee experiences across the United States and Canada. Through subscription-based solutions, the company assists healthcare organizations in areas such as service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. It also delivers market insights solutions that enable healthcare brands to track awareness, perception, and competitive differentiators through real-time assessments and segmentation tools. Founded in 1981 and headquartered in Lincoln, Nebraska, the organization provides tailored experience solutions that help providers manage populations and enhance preventive care.

National Research Corporation experienced annual revenue declines from FY2023 through FY2025, dropping from $151.6M in FY2022 to $137.4M in FY2025. Gross margin shrank from 64.6% in FY2021 to 56.3% in FY2025, while operating margin fell from 34.0% to 16.4% over the same timeframe. Net income decreased from $37.5M in FY2021 to $11.6M in FY2025, resulting in an EPS drop from $1.47 to $0.50. For the trailing twelve months ended June 30, 2026, revenue stood at $140.0M with an operating margin of -0.2% and EPS of $0.25. In the latest quarter, quarterly revenue grew 4.0% year-over-year, while quarterly earnings contracted by 44.0%.

As of June 30, 2026, National Research Corporation held $3.3M in cash and short-term investments against $90.0M in total debt, yielding net debt of $86.7M. Shareholders' equity was $6.5M, resulting in a debt-to-equity ratio of 13.75 and a current ratio of 0.65. Operating cash flow in FY2025 was $26.4M, producing free cash flow of $15.7M after capital expenditures of $10.7M. In FY2025, the company deployed capital by paying $11.0M in dividends and spending $20.2M on share buybacks, contributing to a 14.0% reduction in share count over 5 years.

National Research Corporation trades at a trailing P/E of 80.6x, compared to 24.6x for the median of its US-listed Healthcare peers. Its forward P/E is 17.2x, close to the peer median of 17.3x. The company holds an enterprise value of $564.0M, trading at an EV to EBITDA multiple of 24.1x versus the peer median of 12.0x, and a price-to-sales ratio of 3.2x compared to the peer median of 4.1x. Over the past year, NRC shares gained 78.4%, outpacing the S&P 500 return of 16.8%, but over a 5-year period, the stock declined 46.2% while the S&P 500 gained 83.0%.

National Research Corporation pays a quarterly dividend with an annualized forward rate of $0.64 per share, translating to a dividend yield of 3.18%. The company has paid consecutive dividends for 13 years and generated a 5-year annualized dividend growth rate of 19.9%. Its payout ratio stands at 89.6%, and the last ex-dividend date was September 25, 2026.

Wall Street coverage includes 1 Buy rating, with 0 Strong Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $26.00, representing a 29.0% upside over the last close of $20.15. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $142.6M and EPS of $0.33, reflecting an EPS decrease of 34.0%. For the following fiscal year, 1 analyst projects revenue of $154.5M and EPS of $1.05. Over the last four quarters, the company topped EPS estimates 3 times. The next earnings date is October 26, 2026.

This page is an AI-written research summary of National Research Corporation (NRC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NRC income statement, NRC balance sheet, NRC key metrics, NRC analyst forecast, NRC chart. See the NRC stock overview for the latest quote and news.